3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Unknown
4
Withdrawn
1
Terminated
1
Suspended
1
Not yet recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Liver Neoplasms
1
Carcinoma, Hepatocellular
1
Interventions
Radiotherapy
2
Radiation
2
Nivolumab
2
Magnetic Resonance Spectroscopy
2
lenvatinib
1
Specimen Handling
1
Sorafenib
1
Platinum
1
Photochemotherapy
1
Oxycodone
1
NUC-1031
1
Ketorolac
1
Ketamine
1
Ipilimumab
1
Gemcitabine
1
Folfox protocol
1
Cisplatin
1
CTLA-4 Antigen
1
Biopsy
1
Acetaminophen
1
1,2-diaminocyclohexaneplatinum II citrate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Suspended
×
lenvatinib
×
Clear all
NCT05033522
2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3
Suspended
150 enrolled